Under copyright Constraint(s) on Use: This work is protected by the U.S. Copyright Law (Title 17, U.S.C.). Use of this work beyond that allowed by "fair use" requires written permission of the UC Regents. Responsibility for obtaining permissions and any use and distribution of this work rests exclusively with the user and not the UC San Diego Library. Inquiries can be made to the UC San Diego Library program having custody of the work. Use: This work is available from the UC San Diego Library. This digital copy of the work is intended to support research, teaching, and private study.
Rights Holder and Contact
UC Regents
Description
Dr. Felgner received his PhD in Biochemistry/Neuroscience from Michigan State University in 1978 and also completed Postdoctoral training in Biophysics at University of Virginia. He has over 25 years of experience in the biotechnology industry, including senior research positions at Syntex Research where he developed the first cationic lipid reagent for gene transfer. In 1988, Dr. Felgner became Director of Product Development, Chief Scientific Officer and founder of a start-up company, Vical, Inc. With colleagues at Vical and at the University of Wisconsin, Dr. Felgner made a landmark discovery regarding functional reporter gene sequences and demonstrated that potent antiviral immune responses could be generated following intramuscular injection of plasmids encoding viral antigens. These findings have led to development of a new class of infectious disease vaccines referred to as "DNA vaccines". Dr. Felgner has been issued more than 35 patents and published over 100 scientific papers, and for his numerous biotechnology innovations, he received the Southern California 1996 “Inventor of the Year” award. He went on to found Antigen Discovery, Inc. and served as a Professor at the University of California, Irvine. Born digital Special Collections & Archives, UC San Diego, La Jolla, 92093-0175 (https://lib.ucsd.edu/sca) At the time of this interview, Dr. Felgner was Director of Product Development, Chief Scientific Officer and founder of Vical, Inc. Felgner, Phil. Interview conducted by Mark Jones, July 22, 1997. The San Diego Technology Archive (SDTA), UC San Diego Library, La Jolla, CA.
Type
text
Identifier
ark:/20775/bb16069079
Language
English
Subject
Reporter genes Addition polymerization Life sciences Cationic liposomes DNA vaccines AZT (Drug) Genetic transformation Syntex Pharmaceuticals Vical Antigen Discovery Inc San Diego (Calif.)
If you're wondering about permissions and what you can do with this item, a good starting point is the "rights information" on this page. See our terms of use for more tips.
Share your story
Has Calisphere helped you advance your research, complete a project, or find something meaningful? We'd love to hear about it; please send us a message.
